By engaging NKG2D and overriding the inhibitory signals of killer inhibitory receptors (KIRs) and/or CD94/NKG2A/B, MICA effectively activates NK, γδ T cells and αβ CD8+ T cells to kill virus-infected cells or tumor cells [34,35,36]. Here, CD8A is linked to neoplasm.